-+ 0.00%
-+ 0.00%
-+ 0.00%

Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31

Benzinga·11/10/2026 22:05:03
语音播报
Ladenburg Thalmann analyst Kevin DeGeeter maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $27 to $31.